Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alamar Biosciences, Inc. (ALMR)
USD26.38
-0.68 (-2.50%)
US NASDAQ Healthcare Biotechnology
Address
47071 Bayside Parkway 94538
Fremont, CA, US
Fremont, CA, US
CEO
Justin J. McAnear
Website
www.alamarbio.com
IPO
2026-04-17
CIK 2104204 ISIN US0109111056
Description
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
News Sentiment (7d)
3 articles
- Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research GlobeNewsWire
- Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling Globe News Wire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.38
-0.68 (-2.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
417.7K
Float Shares
5.62M
Free Float %
60.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.81% | -0.65% | +4.41% | +4.41% | +4.41% | +4.41% | +4.41% | +4.41% | +4.41% | +4.41% | +4.41% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
26.38
Low
28.00
+6.2%
Consensus
31.50
+19.4%
Median
31.50
+19.4%
High
35.00
+32.7%
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
31.50
+19.4%
|
| Last Quarter | 2 |
31.50
+19.4%
|
| Last Year | 2 |
31.50
+19.4%
|
| All Time | 2 |
31.50
+19.4%
|
Quality scores
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
9
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 43 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 1.29% | 16.84M | 0.75% |
| 2 | F/M Emerald Life Sciences Innovation ETF LFSC | 0.22% | 162.3K | 0.54% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.02% | 2.45M | 0.24% |
| 4 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 38.3K | 0.25% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.01% | 176.0K | 0.08% |
| 6 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 335.3K | 0.30% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 6.4K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.01% | 9.32M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 60.8K | 0.36% |
| 10 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.01M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.45
Neutral
Ratio by volume
0.84
Neutral
Buys
61
Sells
42
Shares acquired
56.62M
Shares disposed
67.13M
Cash buys
2.00
Cash sales
—
Net activity
-10,513,050
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Witney Frank | Director | J-Other | D | Stock Option (Right to Buy) | 49,627 | 0.59 | 29.3K | 0 | D | ↗ |
| 2026-04-20 | White Timothy Ogden | Officer | J-Other | D | Stock Option (Right to Buy) | 29,357 | 0.59 | 17.3K | 0 | D | ↗ |
| 2026-04-20 | Qiming Corporate GP VI, Ltd. | 10% Owner | C-Conversion | D | Series A-3 Preferred Stock | 6,404,332 | 0.00 | — | 0 | I | ↗ |
| 2026-04-20 | Naclerio Nicholas | Director | C-Conversion | D | Convertible Promissory Note | 0 | 0.00 | — | 0 | I | ↗ |
| 2026-04-20 | McAnear Justin J. | Officer | A-Award | A | Common Stock | 37,220 | 0.00 | — | 37,220 | D | ↗ |
| 2026-04-20 | Luo Yuling | Director / Officer | J-Other | A | Stock Option ((Right to Buy) | 42,334 | 7.60 | 321.7K | 42,334 | D | ↗ |
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C. | 10% Owner | J-Other | A | Common Stock | 5,510,516 | 0.00 | — | 5,510,516 | I | ↗ |
| 2026-04-20 | Chen Shiping | Director / Officer | C-Conversion | A | Class B Common Stock | 72,853 | 0.00 | — | 722,885 | D | ↗ |
| 2026-04-20 | Chambers Rebecca | Director | J-Other | A | Stock Option (Right to Buy) | 140,612 | 7.60 | 1.07M | 140,612 | D | ↗ |
| 2026-04-16 | Witney Frank | Director | — | — | Stock Option (Right to Buy) | 124,069 | 7.60 | 942.9K | 0 | D | ↗ |
| 2026-04-16 | White Timothy Ogden | Officer | — | — | Stock Option (Right to Buy) | 16,333 | 7.60 | 124.1K | 0 | D | ↗ |
| 2026-04-16 | Ratcliffe Ian W | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-04-16 | Qiming Managing Directors Fund VI, L.P. | 10% Owner | — | — | Series A-3 Preferred Stock | 2,648,607 | 0.00 | — | 0 | I | ↗ |
| 2026-04-16 | Naclerio Nicholas | Director | — | — | Convertible Promissory Note | 271,782 | 0.00 | — | 0 | I | ↗ |
| 2026-04-16 | McAnear Justin J. | Officer | — | — | Stock Option (Right to Buy) | 570,719 | 4.62 | 2.64M | 0 | D | ↗ |
| 2026-04-16 | Luo Yuling | Director / Officer | — | — | Founders Preferred Stock | 366,004 | 0.00 | — | 0 | D | ↗ |
| 2026-04-16 | Illumina Innovation Fund II GP, L.L.C. | 10% Owner | — | — | Series A-3 Preferred Stock | 1,321,082 | 0.00 | — | 0 | I | ↗ |
| 2026-04-16 | Chen Shiping | Director / Officer | — | — | Class A Common Stock | 247,311 | 0.00 | — | 0 | D | ↗ |
| 2026-04-16 | Chambers Rebecca | Director | — | — | Stock Option (Right to Buy) | 140,612 | 7.60 | 1.07M | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-141.1K
Shares Outstanding
9.38M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuling Luo | Co-Founder, Chairman & CEO | 662.1K | — |
| Shiping Chen | Co-Founder, COO & Director | 543.1K | — |
| Justin J. McAnear | Chief Financial Officer | 235.8K | male |
| Alex Forrest-Hay | Senior Vice President of Sales | — | male |
| Timothy O. White | President | — | male |
| Xiao-Jun Ma | Chief Technology Officer | — | — |
| Yiyuan Yin | Founder, VP of Technology & Acting Secretary | — | female |
| Stephen A. Williams | Chief Scientific Officer | — | — |
| Anna Berdine | Senior Vice President of Marketing | — | female |
| Micah Litow | Senior VP of AI & Strategic Initiatives | — | male |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALMR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
